Johnson & Johnson (J&J) Collaborates with AdoRx Therapeutics to Develop Therapies for Lung Cancer

 Johnson & Johnson (J&J) Collaborates with AdoRx Therapeutics to Develop Therapies for Lung Cancer

Johnson & Johnson (J&J) Collaborates with AdoRx Therapeutics to Develop Therapies for Lung Cancer

Shots:

  • AdoRx enters into a collaboration with J&J’s Lung Cancer Initiative & J&J Innovations for drug discovery and preclinical candidates. J&J to get an exclusive option to research, develop, and commercialize antagonists within AdoRx’s portfolio
  • The focus of the agreement is to develop therapies with expansion of J&J’s footprints in oncology using AdoRx’s fit-for-purpose adenosine receptor antagonists
  • AdoRx’s fit-for-purpose receptor antagonists modulates high adenosine level present in the tumor targeting the adenosine pathway against cancer

Click here to read full press release/ article | Ref: PRNewswire | Image: Bioworld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post